FDA Adverse Event Injury Summary report: N

AFFERA

MDR report key: 22750702 · Received August 8, 2025

Report

Report Number
9612164-2025-03900
Event Type
Injury
Date Received
August 8, 2025
Date of Event
July 23, 2025
Report Date
November 3, 2025
Manufacturer
MEDTRONIC IRELAND
Product Code
QZI
UDI-DI
00763000973506
PMA / PMN Number
P240013
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
VA, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

PRODUCT EVENT SUMMARY: THE AFR-00001 SPHERE 9 CATHETER WITH LOT 0012794956 WAS RETURNED AND ANALYZED. DURING THE EXTERNAL VISUAL INS PECTION, THE CATHETER WAS CONFIRMED TO BE INTACT WITH NO OBSERVED DEFECTS. ADDITIONALLY, NO TISSUE OR FOREIGN MATERIAL WAS DETECTED ON OR INSIDE THE NITINOL SPHERE. THE CIRRIS TESTER WAS USED TO PERFORM SHORTS AND MAPPING TESTS, WHICH RESULTED IN A FAILURE. AN OPEN CIRCUIT WAS IDENTIFIED AT P4 ELECTRODE. A MULTIMETER AND BREAKOUT FIXTURE WERE USED TO CHECK FOR SHORTS TO THE BRAID, NO SHORTS WERE IDENTIFIED. A DETAILED INSPECTION OF THE LATTICE STRUCTURE WAS CONDUCTED, AND EVIDENCE CORRESPONDING TO THE OPEN CIRCUITS IDENTIFIED DURING THE SHORTS AND MAPPING TESTS WERE CAPTURED. IN CONCLUSION, THE REPORTED "TISSUE IN TIP" WAS NOT CONFIRMED THROUGH TESTING. THE CATHETER FAILED THE RETURNED PRODUCT INSPECTION DUE TO AN OPEN CIRCUIT. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Additional Manufacturer Narrative · 0

PRODUCT EVENT SUMMARY: TWO IMAGES WERE RETURNED AND ANALYZED. TWO IMAGES FROM THE FIELD WERE RETURNED. ONE WAS THE HEPARIN PROTOCOL TRACKING FORM, AND THE OTHER SHOWED THE NITINOL SPHERE OF A SPHERE 9 CATHETER. A FOREIGN MATERIAL OR TISSUE WAS OBSERVED WITHIN THE LATTICE. IN CONCLUSION, THE MATERIAL IN THE TIP WAS CONFIRMED THROUGH ANALYSIS OF THE IMAGE. THE PHYSICAL PRODUCT IS YET TO BE ANALYZED. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Additional Manufacturer Narrative · 0

MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

IT WAS LATER REPORTED THAT THE MATERIAL INSIDE THE THE LATTICE OF THE CATHETER WAS LOOSE, SMALL, AND DARK RED. FIVE FOLLOW-UP DOSES OF BLOOD THINNER MEDICATION WAS REQUIRED.

Description of Event or Problem · 0

IT WAS REPORTED THAT DURING USE OF THE SPHERE-9 CATHETER IN A CARDIAC ABLATION PROCEDURE, CHAR AND THROMBUS FORMATION WERE OBSERVED. THE DEVICE WAS PLACED IN THE LEFT ATRIUM AFTER AN ACTIVATED CLOTTING TIME (ACT) OF 343, DESPITE A RECOMMENDATION TO WAIT UNTIL THE ACT REACHED 350. AFTER INITIAL MAPPING, THE PATIENT EXPERIENCED A DROP IN BLOOD PRESSURE AND TACHYCARDIA. NO EFFUSION WAS DETECTED. THESE SYMPTOMS WERE EVENTUALLY SUSPECTED TO BE A REACTION TO THE ANTICOAGULANT. THE SPHERE-9 CATHETER REMAINED IN THE LEFT ATRIUM DURING THIS PERIOD, WITH NO WORK BEING PERFORMED. TWENTY-FOUR MINUTES LATER, THE ACT MEASURED 262, PROMPTING IMMEDIATE REMOVAL OF THE SPHERE-9 CATHETER. UPON REMOVAL, A CLOT OR THROMBUS WAS OBSERVED INSIDE THE LATTICE OF THE DEVICE. THE SPHERE-9 CATHETER WAS REPLACED, AND THE PATIENT WAS GIVEN A BLOOD THINNER MEDICATION. ACT MEASUREMENTS CONTINUED THROUGHOUT THE PROCEDURE. THE PATIENT STABILIZED, AND THE PROCEDURE WAS COMPLETED SUCCESSFULLY WITH NO FURTHER ISSUES. NO FURTHER PATIENT COMPLICATIONS HAVE BEEN REPORTED AS A RESULT OF THIS EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
227336 AFFERA PERCUTANEOUS CARDIAC ABLATION CATHETER FOR TREATMENT OF ATRIAL FIBRILLATION WITH QZI MEDTRONIC IRELAND AFR-00001 0012794956 00763000973506

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Required Intervention